Abstract
The nociceptin system, which consists of endogenous nociceptin/orphanin FQ and NOP receptors, is present in the central nervous system (CNS), as well as respiratory, cardiovascular, urogenital and gastrointestinal (GI) tissues. It is critically involved in nociception and pain signaling, as well as modulation of hormone and neurotransmitter release, stress responses and reversal of stress-induced analgesia. In the GI tract, the nociceptin system participates in the maintenance of homeostasis by affecting secretion and motility.
Here we give an overview on the nociceptin system in the GI tract. The nociceptin system is an attractive target for novel drugs, which may be effective in the treatment of inflammatory or functional GI disorders, such as inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS).
Keywords: Abdominal pain, gastrointestinal transit, inflammatory bowel diseases, irritable bowel syndrome, nociceptin, Nociceptin / Orphanin FQ receptor.
Current Drug Targets
Title:Nociceptin / Orphanin FQ (NOP) Receptors as Novel Potential Target in the Treatment of Gastrointestinal Diseases
Volume: 14 Issue: 10
Author(s): Marta Sobczak, Maciej Saaga, Martin Storr and Jakub Fichna
Affiliation:
Keywords: Abdominal pain, gastrointestinal transit, inflammatory bowel diseases, irritable bowel syndrome, nociceptin, Nociceptin / Orphanin FQ receptor.
Abstract: The nociceptin system, which consists of endogenous nociceptin/orphanin FQ and NOP receptors, is present in the central nervous system (CNS), as well as respiratory, cardiovascular, urogenital and gastrointestinal (GI) tissues. It is critically involved in nociception and pain signaling, as well as modulation of hormone and neurotransmitter release, stress responses and reversal of stress-induced analgesia. In the GI tract, the nociceptin system participates in the maintenance of homeostasis by affecting secretion and motility.
Here we give an overview on the nociceptin system in the GI tract. The nociceptin system is an attractive target for novel drugs, which may be effective in the treatment of inflammatory or functional GI disorders, such as inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS).
Export Options
About this article
Cite this article as:
Sobczak Marta, Saaga Maciej, Storr Martin and Fichna Jakub, Nociceptin / Orphanin FQ (NOP) Receptors as Novel Potential Target in the Treatment of Gastrointestinal Diseases, Current Drug Targets 2013; 14 (10) . https://dx.doi.org/10.2174/13894501113149990174
DOI https://dx.doi.org/10.2174/13894501113149990174 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ultrasound Imaging of Muscle-tendon Architecture in Neurological Disease: Theoretical Basis and Clinical Applications
Current Medical Imaging Evaluation of Pharmacological Treatment Strategies in Traumatic Brain Injury
Current Pharmaceutical Design Posterior Reversible Encephalopathy Syndrome with Atypical Presentation: A Pictorial Review on MR Imaging Features
Current Medical Imaging Corticotropin Releasing Factor (CRF) Peptide Family and their Receptors: Divergent Actions Influencing Human Physiology
Current Genomics Axotomy Leads to Reduced Calcium Increase and Earlier Termination of CCL2 Release in Spinal Motoneurons with Upregulated Parvalbumin Followed by Decreased Neighboring Microglial Activation
CNS & Neurological Disorders - Drug Targets Targeting of Peripherally Expressed Pain-Related Molecules in Injury- Induced Chronic Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Thiol Proteases: Inhibitors and Potential Therapeutic Targets
Current Medicinal Chemistry Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Neuroprotection by the α2-Adrenoceptor Agonist, Dexmedetomidine, in Experimental Stroke Models
Vascular Disease Prevention (Discontinued) REM Sleep Behavior Disorder and Narcolepsy
CNS & Neurological Disorders - Drug Targets Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer
Current Pharmaceutical Design Atypical Chest Pain in ACS: A Trap Especially for Women
Current Pharmaceutical Design Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design Role of the Osteochondral Unit in the Pathogenesis of Osteoarthritis: Focus on the Potential Use of Clodronate
Current Rheumatology Reviews Neurotoxicity: The Broad Framework of Electron Transfer, Oxidative Stress and Protection by Antioxidants
Current Medicinal Chemistry - Central Nervous System Agents Editorial (Hot Topic: Marine Peptides: Emerging Perspectives for Pharmaceuticals)
Current Protein & Peptide Science Adult Stem Cells and Bioengineering Strategies for the Treatment of Cerebral Ischemic Stroke
Current Stem Cell Research & Therapy Commentary: Histaminergic Drugs Could be Novel Targets for Neuroprotection in CNS Disorders
CNS & Neurological Disorders - Drug Targets Clinical Grade Stem Cell Culture
Recent Patents on Regenerative Medicine Secretoneurin: A New Player in Angiogenesis and Chemotaxis Linking Nerves, Blood Vessels and the Immune System
Current Protein & Peptide Science